PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Tizanidine hydrochloride - Spasticity and muscle spasm

PAD Profile : Tizanidine hydrochloride - Spasticity and muscle spasm Important

Keywords :
spinal cord injury, MS, multiple sclerosis
Brand Names Include :
Tizagelan
Important Information :
Specialist to retain prescribing for first 4 months. Monitor liver function.

Traffic Light Status

Status 1 of 1.

Status :
Blue
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 December 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network recommends the use of tizanidine for the treatment of spasticity.

Tizanidine will be considered BLUE (no information sheet) on the traffic light system.

Prescribing should be retained by the specialist until the patient has been stabilised on the optimal dose which must be a minimum of 4 months.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.02.02. Skeletal muscle relaxants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More